Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | BCR | P11274 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670452 | 0.86 | GRM5 (0.38) | SIRT2HDAC8SMN1; SMN2FYNCNR1 | |
| SCHEMBL19365318 | 0.85 | ALOX15 (0.46) | SIRT2FAAHGSK3BDYRK1A | |
| SCHEMBL19365563 | 0.84 | KMT2A (0.37) | SIRT2FAAHGSK3BDYRK1AGRM5 | |
| SCHEMBL19365759 | 0.83 | FGFR4 (0.41) | FAAHHDAC8SMN1; SMN2ABL1BCR | |
| SCHEMBL19365723 | 0.82 | DYRK1A (0.38) | FAAHABL1GSK3BDYRK1AGRM5 | |
| SCHEMBL19670598 | 0.81 | GSK3B (0.36) | SIRT2ATRFAAHHDAC8SMN1; SMN2 | |
| SCHEMBL17624399 | 0.81 | GSK3B (0.36) | SIRT2ATRFAAHHDAC8SMN1; SMN2 | |
| SCHEMBL16776047 | 0.81 | KARS1 (0.36) | SIRT2ATRFAAHHDAC8SMN1; SMN2 | |
| SCHEMBL16776139 | 0.81 | KARS1 (0.36) | SIRT2ATRFAAHHDAC8SMN1; SMN2 | |
| SCHEMBL19706063 | 0.80 | SIRT2 (0.37) | SIRT2FAAHABL1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SIRT2 3/4885ATR 1867/4885FAAH 977/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | SIRT2 3/4885ATR 1867/4885FAAH 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.